Annual CFO
-$47.34 M
-$55.98 M-647.61%
December 31, 2023
Summary
- As of February 8, 2025, ATNM annual cash flow from operations is -$47.34 million, with the most recent change of -$55.98 million (-647.61%) on December 31, 2023.
- During the last 3 years, ATNM annual CFO has fallen by -$25.72 million (-118.97%).
- ATNM annual CFO is now -647.61% below its all-time high of $8.64 million, reached on December 31, 2022.
Performance
ATNM Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$11.97 M
-$4.00 M-50.21%
September 30, 2024
Summary
- As of February 8, 2025, ATNM quarterly cash flow from operations is -$11.97 million, with the most recent change of -$4.00 million (-50.21%) on September 30, 2024.
- Over the past year, ATNM quarterly CFO has dropped by -$4.49 million (-59.88%).
- ATNM quarterly CFO is now -142.89% below its all-time high of $27.92 million, reached on June 30, 2022.
Performance
ATNM Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$34.81 M
-$850.00 K-2.50%
September 30, 2024
Summary
- As of February 8, 2025, ATNM TTM cash flow from operations is -$34.81 million, with the most recent change of -$850.00 thousand (-2.50%) on September 30, 2024.
- Over the past year, ATNM TTM CFO has increased by +$12.52 million (+26.46%).
- ATNM TTM CFO is now -402.78% below its all-time high of $11.50 million, reached on June 30, 2022.
Performance
ATNM TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ATNM Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -647.6% | -59.9% | +26.5% |
| 3 y3 years | -119.0% | -114.3% | -57.7% |
| 5 y5 years | -130.1% | -113.9% | -62.2% |
ATNM Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -647.6% | at low | -142.9% | +20.6% | -402.8% | +26.9% |
| 5 y | 5-year | -647.6% | at low | -142.9% | +20.6% | -402.8% | +26.9% |
| alltime | all time | -647.6% | at low | -142.9% | +20.6% | -402.8% | +26.9% |
Actinium Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$11.97 M(+50.2%) | -$34.81 M(+2.5%) |
| Jun 2024 | - | -$7.97 M(+8.1%) | -$33.96 M(-14.3%) |
| Mar 2024 | - | -$7.37 M(-1.5%) | -$39.63 M(-16.3%) |
| Dec 2023 | -$47.34 M(-647.6%) | -$7.49 M(-32.7%) | -$47.34 M(-0.6%) |
| Sep 2023 | - | -$11.13 M(-18.5%) | -$47.62 M(+12.8%) |
| Jun 2023 | - | -$13.64 M(-9.5%) | -$42.21 M(+6374.4%) |
| Mar 2023 | - | -$15.08 M(+93.8%) | -$652.00 K(-107.5%) |
| Dec 2022 | $8.64 M(-141.4%) | -$7.78 M(+36.1%) | $8.64 M(-24.0%) |
| Sep 2022 | - | -$5.71 M(-120.5%) | $11.37 M(-1.1%) |
| Jun 2022 | - | $27.92 M(-582.9%) | $11.50 M(-154.7%) |
| Mar 2022 | - | -$5.78 M(+14.4%) | -$21.00 M(+0.7%) |
| Dec 2021 | -$20.87 M(-3.5%) | -$5.05 M(-9.6%) | -$20.87 M(-5.5%) |
| Sep 2021 | - | -$5.59 M(+21.9%) | -$22.07 M(+2.8%) |
| Jun 2021 | - | -$4.58 M(-18.8%) | -$21.48 M(+0.3%) |
| Mar 2021 | - | -$5.64 M(-9.8%) | -$21.41 M(-1.0%) |
| Dec 2020 | -$21.62 M(+0.7%) | -$6.26 M(+25.3%) | -$21.62 M(+6.1%) |
| Sep 2020 | - | -$4.99 M(+10.7%) | -$20.37 M(-2.9%) |
| Jun 2020 | - | -$4.51 M(-22.9%) | -$20.97 M(-3.9%) |
| Mar 2020 | - | -$5.85 M(+16.8%) | -$21.83 M(+1.7%) |
| Dec 2019 | -$21.46 M(+4.3%) | -$5.01 M(-10.5%) | -$21.46 M(+3.5%) |
| Sep 2019 | - | -$5.60 M(+4.4%) | -$20.74 M(-4.7%) |
| Jun 2019 | - | -$5.36 M(-2.3%) | -$21.75 M(+5.6%) |
| Mar 2019 | - | -$5.49 M(+28.0%) | -$20.60 M(+0.1%) |
| Dec 2018 | -$20.57 M(-4.6%) | -$4.29 M(-35.2%) | -$20.57 M(+5.7%) |
| Sep 2018 | - | -$6.61 M(+57.1%) | -$19.45 M(+4.0%) |
| Jun 2018 | - | -$4.21 M(-22.9%) | -$18.71 M(-13.5%) |
| Mar 2018 | - | -$5.46 M(+72.3%) | -$21.64 M(+0.4%) |
| Dec 2017 | -$21.55 M(+3.7%) | -$3.17 M(-46.0%) | -$21.55 M(-4.7%) |
| Sep 2017 | - | -$5.87 M(-17.8%) | -$22.63 M(+1.3%) |
| Jun 2017 | - | -$7.14 M(+32.8%) | -$22.33 M(+4.3%) |
| Mar 2017 | - | -$5.37 M(+26.7%) | -$21.41 M(+3.0%) |
| Dec 2016 | -$20.79 M(+12.1%) | -$4.24 M(-23.9%) | -$20.79 M(+1.3%) |
| Sep 2016 | - | -$5.57 M(-10.5%) | -$20.51 M(+11.2%) |
| Jun 2016 | - | -$6.22 M(+30.8%) | -$18.44 M(+5.5%) |
| Mar 2016 | - | -$4.76 M(+20.0%) | -$17.49 M(-5.7%) |
| Dec 2015 | -$18.54 M | -$3.96 M(+13.3%) | -$18.54 M(-5.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$3.50 M(-33.6%) | -$19.63 M(-3.6%) |
| Jun 2015 | - | -$5.27 M(-9.4%) | -$20.37 M(+15.3%) |
| Mar 2015 | - | -$5.81 M(+15.2%) | -$17.67 M(+23.2%) |
| Dec 2014 | -$14.35 M(+128.0%) | -$5.05 M(+19.1%) | -$14.35 M(+34.8%) |
| Sep 2014 | - | -$4.24 M(+64.9%) | -$10.65 M(+32.6%) |
| Jun 2014 | - | -$2.57 M(+3.2%) | -$8.03 M(+24.0%) |
| Mar 2014 | - | -$2.49 M(+85.3%) | -$6.47 M(+2.8%) |
| Dec 2013 | -$6.29 M(+20.7%) | -$1.34 M(-17.0%) | -$6.29 M(-1.1%) |
| Sep 2013 | - | -$1.62 M(+59.5%) | -$6.37 M(-4.7%) |
| Jun 2013 | - | -$1.02 M(-56.1%) | -$6.68 M(+1.5%) |
| Mar 2013 | - | -$2.31 M(+63.2%) | -$6.58 M(+26.2%) |
| Dec 2012 | -$5.21 M(+907.1%) | -$1.42 M(-26.7%) | -$5.21 M(+20.7%) |
| Sep 2012 | - | -$1.93 M(+111.4%) | -$4.32 M(+81.1%) |
| Jun 2012 | - | -$914.30 K(-3.5%) | -$2.38 M(+63.2%) |
| Mar 2012 | - | -$947.90 K(+81.4%) | -$1.46 M(+182.4%) |
| Dec 2011 | -$517.60 K(-6735.9%) | -$522.50 K(<-9900.0%) | -$517.50 K(>+9900.0%) |
| Sep 2011 | - | $0.00(-100.0%) | -$100.00(-99.2%) |
| Jun 2011 | - | $9100.00(-322.0%) | -$13.30 K(-246.2%) |
| Mar 2011 | - | -$4100.00(-19.6%) | $9100.00(+16.7%) |
| Dec 2010 | $7800.00(-141.5%) | -$5100.00(-61.4%) | $7800.00(-20.4%) |
| Sep 2010 | - | -$13.20 K(-141.9%) | $9800.00(-44.9%) |
| Jun 2010 | - | $31.50 K(-683.3%) | $17.80 K(-228.1%) |
| Mar 2010 | - | -$5400.00(+74.2%) | -$13.90 K(-26.1%) |
| Dec 2009 | -$18.80 K(+34.3%) | -$3100.00(-40.4%) | -$18.80 K(+0.5%) |
| Sep 2009 | - | -$5200.00(+2500.0%) | -$18.70 K(+1.6%) |
| Jun 2009 | - | -$200.00(-98.1%) | -$18.40 K(-13.2%) |
| Mar 2009 | - | -$10.30 K(+243.3%) | -$21.20 K(+51.4%) |
| Dec 2008 | -$14.00 K(-28.6%) | -$3000.00(-38.8%) | -$14.00 K(-28.6%) |
| Sep 2008 | - | -$4900.00(+63.3%) | -$19.60 K(+1.0%) |
| Jun 2008 | - | -$3000.00(-3.2%) | -$19.40 K(+1.0%) |
| Mar 2008 | - | -$3100.00(-64.0%) | -$19.20 K(-2.0%) |
| Dec 2007 | -$19.60 K(+40.0%) | -$8600.00(+83.0%) | -$19.60 K(+78.2%) |
| Sep 2007 | - | -$4700.00(+67.9%) | -$11.00 K(+74.6%) |
| Jun 2007 | - | -$2800.00(-20.0%) | -$6300.00(+80.0%) |
| Mar 2007 | - | -$3500.00 | -$3500.00 |
| Dec 2006 | -$14.00 K | - | - |
FAQ
- What is Actinium Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals annual CFO year-on-year change?
- What is Actinium Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals quarterly CFO year-on-year change?
- What is Actinium Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals TTM CFO year-on-year change?
What is Actinium Pharmaceuticals annual cash flow from operations?
The current annual CFO of ATNM is -$47.34 M
What is the all time high annual CFO for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high annual cash flow from operations is $8.64 M
What is Actinium Pharmaceuticals annual CFO year-on-year change?
Over the past year, ATNM annual cash flow from operations has changed by -$55.98 M (-647.61%)
What is Actinium Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ATNM is -$11.97 M
What is the all time high quarterly CFO for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high quarterly cash flow from operations is $27.92 M
What is Actinium Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, ATNM quarterly cash flow from operations has changed by -$4.49 M (-59.88%)
What is Actinium Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ATNM is -$34.81 M
What is the all time high TTM CFO for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high TTM cash flow from operations is $11.50 M
What is Actinium Pharmaceuticals TTM CFO year-on-year change?
Over the past year, ATNM TTM cash flow from operations has changed by +$12.52 M (+26.46%)